We are excited to announce our partnership with Google Cloud to use their Natural Language Processing (NLP) technology to help us better understand the unstructured data in cancer patients’ medical records.
This is a key part of our mission to provide the most comprehensive cancer care possible by leveraging the latest advances in data science and technology.
2022 has been a time of extraordinary growth at COTA including many new faces that we are proud to welcome to our team.
After working at one of the world’s leading global clinical research organizations, Noel joins us to continue his work advocating for patients and helping to advance therapeutic and diagnostic options for all.
COTA President & CEO, Miruna Sasu, gave a keynote speech at the DIA 2022 Global Annual Meeting on healthcare disparities. She shared her personal story of how her family benefited from clinical trials and how she is now working to open those opportunities for others.
We are so excited to welcome our 8 new interns for our 2022 internship program – learn a little bit more about each the newest additions to COTA.
After two years, COTA was back together in NYC for an in-person all-hands meeting. As much as we have learned to adapt to the world of remote work, there is no substitute for the connection, collaboration, and energy that comes from physically being in the same space.
Miami Cancer Institute Takes Action To Address Inequities in Cancer Care with Expanded COTA, Inc. Collaboration
Miami Cancer Institute, part of Baptist Health South Florida, will leverage COTA’s Real-World Analytics to drive standardization of care across all cancer patients
ViVE 2022 brought together thought leaders addressing key disparities and the future of healthcare. Our own C.K. Wang, alongside expert oncologists and technology innovators stressed the need for understanding what “precision oncology” really is.
I’m delighted to be leading COTA at this pivotal moment in history, when precision oncology and data science are advancing together at lightning speed. By working with partners across the healthcare continuum, we can guide cancer patients and their families down the path to clear, safe, personalized, and effective cancer care.
In this article in the scientific journal Blood Reviews, COTA researchers and collaborators share their views on the many sources of RWD and how to assess fit-for-purpose for use in RWE generation. They also review promising use cases for RWD, particularly for hematologic malignancies.